Does cA19-9 Normalization During Pre-operative Treatment predict Longer Survival for Patients with Locally Progressed Pancreatic Cancer?
Pre-operative CA19-9 decline can guide treatment duration in patients with BR/LA PDAC. We endorse 6 months of therapy except in those patients whose values normalize, where surgery can be considered after a shorter course.
Fatigue is a promising indicator of risk for conversion to confirmed moderate-severe disability in RRMS patients.